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Abstracts / Osteoarthritis and Cartilage 21 (2013) S63–S312 S143Conclusions: In 2 years of follow up substantial numbers of participants
with complaints due to early OA could be diagnosed according to
clinical or radiographic ACR criteria with either hip or knee OA after two
years of follow up. Speciﬁc factors associated with this progression
found in the hip group: morning stiffness of the hip, pain medication
use, and Heberden's nodes. In the knee group Heberden's nodes were
associated with the diagnosis of knee OA.
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STRONTIUM RANELATE INCREASES THE NUMBER OF PATIENTS WITH
IMPROVEMENT IN OSTEOARTHRITIS SYMPTOMS COMPARED TO
PLACEBO IN THE SEKOIA STUDY
O. Bruyere y, P. Richette z, N. Bellamy x, J. Brown k, R. Chapurlat {,
X.-J. Chevalier #, E. Czerwinski yy, J.-P. Devogelaer zz, L. March xx,Placebo (N ¼ 472) n (%) SrRan 2 g (N ¼ 454) n (%) Difference relative to placebo [95% CI] p-value
WOMAC
Responders 20% 297 (64.0) 317 (72.0) 8.0 [2.0 ; 14.1] 0.010
Responders 50% 208 (44.8) 223 (50.7) 5.9 [-0.7 ; 12.4] 0.078
WOMAC Pain subscore
Patients above MPCI threshold (9.7mm) 255 (55) 289 (65.5) 10.6 [4.2 ; 16.9] 0.001
WOMAC Stiffness subscore
Patients above MPCI threshold (10mm) 247 (52.8) 270 (60.1) 7.4 [0.9 ; 13.8] 0.025
WOMAC Physical function subscore
Patients above MPCI threshold (9.3mm) 229 (49.1) 257 (57.9) 8.7 [2.3 ; 15.2] 0.008
Patients above MCII threshold (-9.1mm) 231 (49.6) 257 (57.9) 8.3 [1.9 ; 14.8] 0.012
Knee pain by VAS
Responders 20% 325 (69.7) 336 (76.0) 6.3 [0.5 ; 12.0] 0.034
Responders 50% 249 (53.4) 263 (59.5) 6.1 [-0.4 ; 12.5] 0.065
Patients above MCII threshold (-19.9mm) 277 (59.4) 302 (67.7) 8.3 [2.1; 14.5] 0.010
OMERACT-OARSI-like responders 221 (47.0) 244 (54.0) 7.0 [0.5 ; 13.4] 0.035
MPCI responders were statistically signiﬁcantly greater fromM18 (pain and functionWOMAC sub-scores, p¼ 0.003 and p¼ 0.013, respectively), and after 2 years for stiffness
sub-score (p¼ 0.008), being close to statistical signiﬁcance (p¼ 0.051) for physical function sub-score. When considering withdrawn patients as non-responders, results were
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Purpose: In SEKOIA study, strontium ranelate 2g/day (SrRan) has
shown structure-modifying activity associated with statistically signif-
icant symptomatic improvement compared to placebo in patients with
knee osteoarthritis (OA). The purpose of this analysis was to determine
the proportion of patients considered as symptomatic responders as per
WOMAC pain sub-score or pain VAS improvement and OMERACT-
OARSI-like responders, as well as the number of patients reaching MPCI
(Minimal Perceptible Clinical Improvement) and MCII (Minimal Clinical
Important Improvement).
Methods: SEKOIA study was a double-blind, placebo-controlled,
randomized, international 3-year study aiming to demonstrate the
effects of strontium ranelate on the radiographic progression of knee
osteoarthritis. It included men and women over 50 years old, with
symptomatic primary knee OA (at least 40 on a 100 mm visual analog
scale (VAS) on most days of the previous month, Kellgren and Lawrence
[KL] grade 2 or 3, and joint space width [JSW] 2.5-5 mm). Symptomswere assessed every 6 months over 3 years using the WOMAC ques-
tionnaire and a 100 mm VAS. Proportions of patients with an
improvement of at least 20% or 50% from baseline of their WOMAC pain
sub-score or pain VAS, proportion of OMERACT-OARSI-like responders
(calculated using improvement in pain and function but not patient's
global assessment as it was not assessed in this study) and percentages
of patients reaching MPCI or MCII published values, were compared
between groups using a chi2 test.
Results: The ITT population included 1371 (82%) patients presenting at
baseline, mean  SD, an age of 637 years, BMI of 305 kg/m2, VAS of
5422 mm, and WOMAC of 13262 mm. 61% were KL grade II and 69%
were female. Over 3 years, a greater percentage of patients treated with
SrRan 2g were considered as symptomatic responders compared to
placebo:Conclusions: Treatment with SrRan is associated with a greater
number of patients with relevant improvement in symptoms. This can
be evidenced from M18 considering MPCI responders.265
STRONTIUM RANELATE PREVENTS RADIOLOGICAL PROGRESSION IN
PATIENTS WITH PRIMARY KNEE OSTEOARTHRITIS: A RESPONDERS
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Purpose: Strontium ranelate (SrRan) has demonstrated a structure-
modifying activity associated with symptoms improvement in patients
with knee osteoarthritis (OA) in a large, randomised, placebo-
controlled, double-blind phase-III 3-year study (SEKOIA study). The aim
of this analysis was to describe the proportion of patients in whom
radiological OA progression was prevented on each treatment group,
when considering different cut-offs of JSN.
Methods: The SEKOIA study included patients with symptomatic
primary knee OA (Kellgren and Lawrence [KL] grade 2 or 3, joint space
width [JSW] 2.5-5 mm) randomly allocated to SrRan 1 or 2 g/day, or
placebo. Primary endpoint was radiographic change in JSW of the
medial tibiofemoral compartment from baseline to LOCF. JSW was
measured yearly using a validated computer-assisted centralised
